There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
The conversation discusses hair loss treatments, specifically seeking a 15% glycyrrhizic acid formula without additional ingredients. It also mentions the potential opposite effects of glycyrrhizic acid on humans compared to rats.
The conversation is about a user complaining about the strong smell of a stemoxydine serum used for hair loss. Other users suggest that the product might be counterfeit due to its unpleasant odor.
Clascoterone showed promising initial results for hair regrowth but failed to replicate them, leading to disappointment. Users discuss combining it with minoxidil and other treatments, noting its current availability only in lower concentrations.
A user is seeking a trusted supplier for RU58841 in the UK, expressing doubts about their current source, rudirect, and considering Anagenic and receptorchem. They are asking for recommendations for other suppliers.
The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.
Dutasteride capsules should not be bitten or opened due to their foul taste and potential caustic effects. Users shared experiences of accidentally biting capsules and the unpleasant taste, with some suggesting swallowing techniques to avoid this.
The ineffectiveness of Strut Health's dutasteride capsules, which are filled with raw powder instead of liquid and don't contain any buffering agents that would allow for absorption into the bloodstream. It is suggested to use other brands of liquid-filled dutasteride capsules for better results.
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.
A user shared their successful hair loss regimen, which includes New Nordic Hair Gro vitamins, Shea Moisture Jamaican Black Castor Oil Leave-In Conditioner, and NAC supplements. They reported reduced hair shedding, thicker hair, and improved hair texture.
Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.
Abyssinian oil, argan oil, and Batana oil are being discussed for their potential effectiveness in hair growth. The conversation questions whether these oils are beneficial or a scam.
RU58841 is discussed as an effective hair loss treatment, with some users experiencing regrowth and reduced shedding, but concerns about safety and sourcing are raised. Users advise against purchasing from Amazon, recommending reputable sources and cautioning about potential side effects like cardiovascular issues.
Dutasteride studies for hair loss are often sponsored by GlaxoSmithKline, raising concerns about potential bias. Despite this, some users report positive results with dutasteride and oral minoxidil, while others remain skeptical of industry-funded research.
PP405 might take 3-4 years to be available, but some claim Everychem offers a similar product, though its effectiveness is debated. Users discuss the risks of using untested grey market products and the potential for adverse effects.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.
GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.
The user is using Avodart Dutasteride 0.5mg and Roma Minoxidil 2.5mg to combat hair loss, with advice suggesting this combination is effective but may take 3-6 months to show results. The user is considering whether to continue the treatment or buzz their hair, seeking reassurance and advice from others.
The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.